Degarelix
- Generic Name
- Degarelix
- Brand Names
- Firmagon, Degarelix Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C82H103ClN18O16
- CAS Number
- 214766-78-6
- Unique Ingredient Identifier
- SX0XJI3A11
- Background
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone s...
- Indication
Degaralix is used for the management of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
- Associated Therapies
- -
A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
- Conditions
- First Posted Date
- 2014-06-10
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Kenneth Pienta, MD
- Registration Number
- NCT02159690
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
- First Posted Date
- 2014-05-12
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT02135445
Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT02020070
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 206
- Registration Number
- NCT02015871
- Locations
- 🇨🇳
Peking University People's Hospital (there may be multiple sites in this country), Beijing, Beijing, China
TRial on the Endocrine Activity of Neoadjuvant Degarelix
- Conditions
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 51
- Registration Number
- NCT02005887
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Policlinico S. Orsola-Malpighi di Bologna, Bologna, Italy
🇮🇹Istituto Toscana Tumori, Prato, Italy
🇮🇹Ospedale degli Infermi, Rimini, Italy
Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 120
- Registration Number
- NCT01994239
- Locations
- 🇫🇷
Hôpital Saint Louis, Paris, France
🇫🇷Clinique Sainte-Marguerite, Hyeres, France
🇫🇷Institut de Cancérologie de l'Ouest -Site Paul Papin, Angers, France
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT01990196
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 234
- Registration Number
- NCT01964170
Impact of Estradiol Addback
- Conditions
- Interventions
- First Posted Date
- 2013-05-27
- Last Posted Date
- 2019-06-07
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 43
- Registration Number
- NCT01862835
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 310
- Registration Number
- NCT01786265
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.